Biomedical Research Education & Training
Faculty Member

Giltnane, Jennifer, MD, PhD
Assistant Professor of Pathology, Microbiology and Immunology

Lab Url: N/A

Phone Number: 615-875-1004

Email Address:

Giltnane, Jennifer's picture
Academic history
BS, University of Tennessee, Knoxville
MD, Yale University School of Medicine
PhD, Yale University

Office Address   Mailing Address

PRB 649

777 Preston Research Building 37232-6307

Patient Care Specialty
Anantomic Pathology, Laboratory Medicine, Clinical Pathology

Research Description
I am continuing my career at Vanderbilt with a focus on biomarker discovery and validation for the prediction of treatment resistance and recurrence in breast cancer. Currently, I am exploring the mechanisms of resistance to endocrine therapy utilizing tissue from a presurgical tissue trial of aromatase inhibitor treatment in operable ER+ breast cancers. Through multi-platform molecular profiling of these tumors, I hope to identify actionable somatic alterations and uncover additional therapeutic liabilities to overcome treatment resistance. A long-term goal is to develop a cost-effective, protein-based biomarker assay to predict endocrine-response in ER+ breast cancer, informed by my experience with quantitative protein measurements in tissue.

Second, in a collaborative project currently funded by a DOD Breast Cancer Research Program Breakthrough Award, I am determining the incidence and impact of JAK2 alterations in triple negative breast cancer. My research partner discovered JAK2 amplification in residual tumors after neoadjuvant chemotherapy. We have evidence that clonal populations in primary tumors containing this change are selected by treatment pressure, leading to a more aggressive tumor profile.

Finally, in an effort funded by the Patient-Centered Outcomes Research Institute (PCORI), I am working to establish an institution-wide pathological sample biorepository (PathLink), which will be linked to the local medical record databases, the Research (RD, identified) and Synthetic Derivatives (SD, deidentified). Our initial objective is to seed this research resource with ???on the shelf??? remnant DNA samples and tissues. Initial efforts will be focused on tumor samples highly annotated in the medical record, a subset of which has been profiled already in the molecular genetic pathology laboratory. These specimens are invaluable resource to my own research, and also to the research community, but only if they are quickly accessible to the investigators that need them. We are proposing a system that will allow banking of these specimens while also preserving tissue for future clinical assays if necessary.

Clinical Interests
Biobanking and tissue management for clinical studies, tissue microarray studies of clinical trial cohorts

David L. Rimm, Jennifer M. Giltnane, Lisa Ryden. Methods for a Predictive Diagnostic Test for Tamoxifen. U.S. Patent Application #12/215,458. Filed: 1/29/2007.

Balko, JM, Giltnane, JM, Wang, K, Schwarz, LJ, Young, CD, Cook, RS, Owens, P, Sanders, ME, Kuba, MG, S??nchez, V, Kurupi, R, Moore, PD, Pinto, JA, Doimi, FD, G??mez, H, Horiuchi, D, Goga, A, Lehmann, BD, Bauer, JA, Pietenpol, JA, Ross, JS, Palmer, GA, Yelensky, R, Cronin, M, Miller, VA, Stephens, PJ, Arteaga, CL. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov, 4(2), 232-45, 2014

Giltnane, JM, Balko, JM. Rationale for targeting the Ras/MAPK pathway in triple-negative breast cancer. Discov Med, 17(95), 275-83, 2014

Jeselsohn, R, Yelensky, R, Buchwalter, G, Frampton, G, Meric-Bernstam, F, Gonzalez-Angulo, AM, Ferrer-Lozano, J, Perez-Fidalgo, JA, Cristofanilli, M, G??mez, H, Arteaga, CL, Giltnane, J, Balko, JM, Cronin, MT, Jarosz, M, Sun, J, Hawryluk, M, Lipson, D, Otto, G, Ross, JS, Dvir, A, Soussan-Gutman, L, Wolf, I, Rubinek, T, Gilmore, L, Schnitt, S, Come, SE, Pusztai, L, Stephens, P, Brown, M, Miller, VA. Emergence of constitutively active estrogen receptor-?? mutations in pretreated advanced estrogen receptor-positive breast cancer. Clin Cancer Res, 20(7), 1757-67, 2014

Ondrejka, SL, Jegalian, AG, Kim, AS, Chabot-Richards, DS, Giltnane, J, Czuchlewski, DR, Shetty, S, Sekeres, MA, Yenamandra, A, Head, D, Jagasia, M, Hsi, ED. PDGFRB-rearranged T-lymphoblastic leukemia/lymphoma occurring with myeloid neoplasms: The missing link supporting a stem cell origin. Haematologica, 2014

Owens, P, Pickup, MW, Novitskiy, SV, Giltnane, JM, Gorska, AE, Hopkins, CR, Hong, CC, Moses, HL. Inhibition of BMP signaling suppresses metastasis in mammary cancer. Oncogene, 2014

Chmielecki, J, Peifer, M, Viale, A, Hutchinson, K, Giltnane, J, Socci, ND, Hollis, CJ, Dean, RS, Yenamandra, A, Jagasia, M, Kim, AS, Dav??, UP, Thomas, RK, Pao, W. Systematic screen for tyrosine kinase rearrangements identifies a novel C6orf204-PDGFRB fusion in a patient with recurrent T-ALL and an associated myeloproliferative neoplasm. Genes Chromosomes Cancer, 51(1), 54-65, 2012

Anagnostou, VK, Welsh, AW, Giltnane, JM, Siddiqui, S, Liceaga, C, Gustavson, M, Syrigos, KN, Reiter, JL, Rimm, DL. Analytic variability in immunohistochemistry biomarker studies. Cancer Epidemiol Biomarkers Prev, 19(4), 982-91, 2010 PMCID:2894764

Rokicki, J, Das, PM, Giltnane, JM, Wansbury, O, Rimm, DL, Howard, BA, Jones, FE. The ERalpha coactivator, HER4/4ICD, regulates progesterone receptor expression in normal and malignant breast epithelium. Mol Cancer, 9, 150, 2010 PMCID:2894764

Giltnane, JM, Moeder, CB, Camp, RL, Rimm, DL. Quantitative multiplexed analysis of ErbB family coexpression for primary breast cancer prognosis in a large retrospective cohort. Cancer, 115(11), 2400-9, 2009 PMCID:2756449

Moeder, CB, Giltnane, JM, Moulis, SP, Rimm, DL. Quantitative, fluorescence-based in-situ assessment of protein expression. Methods Mol Biol, 520, 163-75, 2009 PMCID:2894764

Giltnane, JM, Molinaro, A, Cheng, H, Robinson, A, Turbin, D, Gelmon, K, Huntsman, D, Rimm, DL. Comparison of quantitative immunofluorescence with conventional methods for HER2/neu testing with respect to response to trastuzumab therapy in metastatic breast cancer. Arch Pathol Lab Med, 132(10), 1635-47, 2008 PMCID:2756449

*Moeder, CB, *Giltnane, JM, Harigopal, M, Molinaro, A, Robinson, A, Gelmon, K, Huntsman, D, Camp, RL, Rimm, DL. *Authors contributed equally . Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its implications for tissue microarray based assessment of outcome. J Clin Oncol, 25(34), 5418-25, 2007 PMCID:2397537

Giltnane, JM, Ryd??n, L, Cregger, M, Bendahl, PO, Jirstr??m, K, Rimm, DL. Quantitative measurement of epidermal growth factor receptor is a negative predictive factor for tamoxifen response in hormone receptor positive premenopausal breast cancer. J Clin Oncol, 25(21), 3007-14, 2007 PMCID:2397537

Rimm, DL, Giltnane, JM, Moeder, C, Harigopal, M, Chung, GG, Camp, RL, Burtness, B. Bimodal population or pathologist artifact (Letter to the editor). J Clin Oncol, 25(17), 2487-8, 2007 PMCID:2397537

Dolled-Filhart, M, McCabe, A, Giltnane, J, Cregger, M, Camp, RL, Rimm, DL. Quantitative in situ analysis of beta-catenin expression in breast cancer shows decreased expression is associated with poor outcome. Cancer Res, 66(10), 5487-94, 2006 PMCID:2397537

Giltnane, JM, Murren, JR, Rimm, DL, King, BL. AQUA and FISH analysis of HER-2/neu expression and amplification in a small cell lung carcinoma tissue microarray. Histopathology, 49(2), 161-9, 2006 PMCID:2397537

Giltnane, JM, Rimm, DL. Technology insight: Identification of biomarkers with tissue microarray technology. Nat Clin Pract Oncol, 1(2), 104-11, 2004 PMCID:2397537

Rosenwald, A, Wright, G, Wiestner, A, Chan, WC, Connors, JM, Campo, E, Gascoyne, RD, Grogan, TM, Muller-Hermelink, HK, Smeland, EB, Chiorazzi, M, Giltnane, JM, Hurt, EM, Zhao, H, Averett, L, Henrickson, S, Yang, L, Powell, J, Wilson, WH, Jaffe, ES, Simon, R, Klausner, RD, Montserrat, E, Bosch, F, Greiner, TC, Weisenburger, DD, Sanger, WG, Dave, BJ, Lynch, JC, Vose, J, Armitage, JO, Fisher, RI, Miller, TP, LeBlanc, M, Ott, G, Kvaloy, S, Holte, H, Delabie, J, Staudt, LM. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell, 3(2), 185-97, 2003 PMCID:309637

Rosenwald, A, Wright, G, Chan, WC, Connors, JM, Campo, E, Fisher, RI, Gascoyne, RD, Muller-Hermelink, HK, Smeland, EB, Giltnane, JM, Hurt, EM, Zhao, H, Averett, L, Yang, L, Wilson, WH, Jaffe, ES, Simon, R, Klausner, RD, Powell, J, Duffey, PL, Longo, DL, Greiner, TC, Weisenburger, DD, Sanger, WG, Dave, BJ, Lynch, JC, Vose, J, Armitage, JO, Montserrat, E, L??pez-Guillermo, A, Grogan, TM, Miller, TP, LeBlanc, M, Ott, G, Kvaloy, S, Delabie, J, Holte, H, Krajci, P, Stokke, T, Staudt, LM, , . The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med, 346(25), 1937-47, 2002 PMCID:309637

Shaffer, AL, Lin, KI, Kuo, TC, Yu, X, Hurt, EM, Rosenwald, A, Giltnane, JM, Yang, L, Zhao, H, Calame, K, Staudt, LM. Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity, 17(1), 51-62, 2002 PMCID:309637

Postdoctoral Position Available

Postdoctoral Position Details
No position available at this time.

Updated Date